Abstract We hypothesized that the effect of hyperbaric oxygen (HBO) on bone formation is increased via osteogenic differentiation of bone marrow stromal cells (BMSCs), which is regulated by Wnt3a/β-catenin signaling. Our in vitro data showed that HBO increased cell proliferation, Wnt3a production, LRP6 phosphorylation, and cyclin D1 expression in osteogenically differentiated BMSCs. The mRNA and protein levels of Wnt3a, β-catenin, and Runx2 were upregulated while those of GSK-3β were downregulated after HBO treatment. The relative density ratio (phospho-protein/protein) of Akt and GSK-3β was both up-regulated while that of β-catenin was down-regulated after HBO treatment. We next investigated whether HBO affects the accumulation of β-catenin. Our Western blot analysis showed increased levels of translocated β-catenin that stimulated the expression of target genes after HBO treatment. HBO increased TCF-dependent transcription, Runx2 promoter/ Luc gene activity, and the expression of osteogenic markers of BMSCs, such as alkaline phosphatase activity, type I collagen, osteocalcin, calcium, and the intensity of Alizarin Red staining. HBO dose dependently increased the bone morphogenetic protein (BMP2) and osterix production. We further demonstrated that HBO increased the expression of vacuolar-ATPases, which stimulated Wnt3a secretion from BMSCs. Finally, we showed that the beneficial effects of HBO on bone formation were related to Wnt3a/β-catenin signaling in a rabbit model by histology, mechanical testing, and immunohistochemical assays. Accordingly, we concluded that HBO increased the osteogenic differentiation of BMSCs by regulating Wnt3a secretion and signaling.
Introduction
Bone loss induced by hypoxia is associated with various pathophysiological conditions such as ischemia (Vogt et al., 1997) . The long-term culturing of human bone marrow stromal cells (BMSCs) under hypoxia conditions promotes a genetic program that maintains their undifferentiated and multi-potent status (Basciano et al., 2011) . Hypoxia induces BMSC proliferation and enhances long-term BMSC expansion, but results in a population with impaired osteogenic differentiation potential (Fehrer et al., 2007; Pattappa et al., 2013) . Hypoxia inhibits osteogenic differentiation in BMSCs by regulating Runx2 via the basic helix-loop-helix (bHLH) transcription factor TWIST (Yang et al., 2011) .
Hyperbaric oxygen (HBO) therapy is a safe noninvasive modality that increases the oxygen tension of tissues and microvasculature (Korhonen et al., 1999) . HBO increases the expression of placental growth factor in BMSCs (Shyu et al., 2008) , fibroblast growth factor (FGF)-2 in osteoblasts (Hsieh et al., 2010) , and the Wnt-3 protein in neural stem cells (Wang et al., 2007) . The BMSC population contains a subset comprised of skeletal stem cells, which contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, and adipocyte in vivo, and cartilage in pellet cultures in vitro (Pittenger et al., 1999) . Previous studies have suggested that Wnt signaling could be used to stimulate bone healing (Minear et al., 2010) and fracture repair (Komatsu et al., 2010) . We first reported the beneficial effects of HBO on bone lengthening in a rabbit model (Ueng et al., 1998) . However, little is known about the effects of HBO on the Wnt signaling pathway in BMSCs.
Autocrine and paracrine Wnt signaling operates in stem cell populations and regulates mesenchymal lineage specification. The target cells for the Wnt proteins expressed by BMSCs may be either BMSCs themselves or other cell types in the bone marrow (Etheridge et al., 2004) . Wnt proteins are secreted lipid-modified signaling molecules that influence multiple processes during animal development (Nusse, 2003) . The Wnt family of signaling proteins mediates cellcell communication (Lorenowicz and Korswagen, 2009; Port and Basler, 2010) . In the absence of the Wnt protein, β-catenin is phosphorylated by glycogen synthase kinase-3β (GSK-3β) and subsequently degraded by proteasomes (Zeng et al., 2005) . On target cells, secreted Wnt proteins interact with the receptors Frizzled and low-density lipoprotein receptor-related (LRP) 5/6 to activate the β-catenin pathway (Logan and Nusse, 2004) . Activation of the Frizzled receptor complex results in the inhibition of a phosphorylation cascade that stabilizes intracellular β-catenin levels. β-Catenin is subsequently translocated into the nucleus to form a transcriptionally active β-catenin T-cell factor (TCF)/lymphoid enhancer factor (LEF) DNA-binding complex that regulates the Wnt target gene. Among Wnt family members, Wnt3a is involved in the proliferation and differentiation of BMSCs (De Boer et al., 2004) . Once BMSCs are committed to the osteogenic lineage, canonical Wnt signaling stimulates their differentiation (Ling et al., 2009; Eijken et al., 2008) . Canonical Wnt signaling promotes osteogenesis by directly stimulating Runx2 gene expression (Gaur et al., 2005) . Runx2 activates osteocalcin, which is an osteoblast-specific gene expressed by differentiated osteoblasts (Ducy, 2000) .
Vacuolar ATPases (V-ATPases) are large multi-subunit complexes that are organized into V0 and V1 domains, which operate by a rotary mechanism (Forgac, 2007) . V-ATPasedriven proton pumping and organellar acidification are essential for vesicular trafficking along both the exocytotic and endocytotic pathways of eukaryotic cells. In Wnt producing cells, vacuolar acidification is required for Wnt signaling (Cruciat et al., 2010; Coombs et al., 2010) . The secretion of Wnt3a protein into the cell culture medium was shown to be dependent on vacuolar pH. Moreover, acidification inhibitor was shown to decrease secreted and increase cell-associated Wnt3a. The inhibition of V-ATPase blocks Wnt3a secretion and inhibits Wnt/β-catenin signaling both in cultured human cells and in vivo (Coombs et al., 2010) .
In the present study, we found that HBO increased cell proliferation, LRP6 phosphorylation, and cyclin D1 expression in osteogenically differentiated BMSCs. HBO increased the osteogenic differentiation of BMSCs via regulation of Wnt3a signaling as well as increased the TCF-dependent transcription and Runx2 promoter/Luc gene activity. Because Wnt/β-catenin signaling is an upstream activator of BMP2 expression in osteoblasts, we found that HBO dose dependently increased the BMP2 and osterix production. Since endosomal acidification is an essential function of the Wnt secretion pathway, we further demonstrated that HBO increased the expression of V-ATPases to stimulate Wnt3a secretion. Finally, we showed the beneficial effects of HBO on bone formation via Wnt/β-catenin signaling regulation in a rabbit model.
Materials and methods

In vitro study
The experimental protocol was approved by the human subjects Institutional Review Board of the Chang Gung Memorial Hospital.
Surgical procedures
We harvested BMSCs from patients who underwent iliac bone grafting for spine fusion. During bone graft harvesting, 10 mL of bone marrow was aspirated and collected in a heparin-rinsed syringe.
Isolation and cultivation of BMSCs
Each marrow sample was washed with Dulbecco's phosphatebuffered saline (DPBS). Up to 2 × 10 8 nucleated cells in 5 mL of DPBS were loaded onto 25 mL of Percoll cushion (Pharmacia Biotech). A density gradient was used as the isolation procedure to eliminate unwanted cell types that were present in the marrow aspirate. A small percentage of cells were isolated from the density interface at 1.073 g/mL. The cells were re-suspended and plated at 2 × 10 5 cells in T-75 flasks. The cells were maintained in Dulbecco's Modified Eagle's Medium-Low Glucose (DMEM-LG; Gibco, Grand Island, NY) that contained 20% fetal bovine serum (FBS) and antibiotics at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. After 7 d of primary culturing, the non-adherent cells were removed by changing the medium. The BMSCs grew as symmetric colonies and were subcultured at 10 to 14 d by treatment with 0.05% trypsin (Gibco) and seeded into fresh flasks.
Flow cytometric analysis of surface antigen expression When confluent, the BMSCs were passaged 1 in 3, and a sample was analyzed for MSC marker expression by flow cytometry. The cells were washed in phosphate-buffered saline (PBS), and then removed from the flask by 0.05% trypsin (Gibco). 1 × 10 5 cells were incubated with each mouse monoclonal primary antibody at 4°C for 30 min. Mouse FITC-conjugated anti-CD105 antibody (1:100 dilution), mouse PE-conjugated anti-CD146 antibody (1:100 dilution), and mouse FITC-conjugated anti-CD34 antibody (1:100 dilution) were purchased from Becton Dickinson (Oxford, UK). Mouse FITC-conjugated anti-αSMA antibody (1:25 dilution) was purchased from Abcam (Cambridge, UK). Mouse PE-conjugated anti-STRO-1 antibody (1:50 dilution) was purchased from Santa Cruz (CA, USA). After wash, the cells were resuspended in 500 μL wash buffer and analyzed on a BD flow cytometer (Oxford, UK).
Cell exposure to intermittent HBO Cells were cultured in complete medium (DMEM-LG containing 10% FBS and antibiotics) and the osteogenic groups were cultured in osteogenic induction medium (DMEM-LG containing 10% FBS, antibiotics, 100 μM ascorbate-2 phosphate, 100 nM dexamethasone, and 10 mM β-glycerophosphate). Control cells were maintained in 5% CO 2 /95% air throughout the experiment. The hyperoxic cells were exposed to 100% O 2 for 25 min and then to 5% CO 2 /95% air for 5 min at 2.5 ATA (atmospheres absolute) in a hyperbaric chamber (Huxley Corporation, Taipei, Taiwan) for 90 min every 36 h.
Cell proliferation assay
Cell proliferation was quantified using the WST-1 cell proliferation reagent (Roche, Penzberg, Germany) according to the manufacturer's protocol. About 2 × 10 3 BMSCs/well were plated on 24-well cell culture plates and incubated at 37°C in 5% CO 2 /95% air. After 12 h, the culture medium was changed to complete or osteogenic induction medium with 10% FBS and the cells were exposed to HBO (day 1). Cells were incubated for 36 h after HBO treatment, 100 μL/well of WST-1 was added, and then incubated for 4 h. The absorbance of each sample was determined in triplicate using an ELISA plate-reader (MRX; Dynatech Labs) at 440 nm. On days 4, 7, 10 and 14, the absorbance of each sample was determined as described above.
RNA preparation and real-time quantitative polymerase chain reaction (Q-PCR) analysis About 2.5 × 10 5 BMSCs were plated onto 100 mm cell culture dishes. After culturing for 1, 4, and 7 d with or without HBO treatment, the cultured cells were rinsed with PBS. Total RNA was extracted using a Qiagen RT kit (Qiagen, USA) according to the manufacturer's instructions. Each RNA sample was further purified using an RNeasy Mini Column (Qiagen). The RNA concentration was evaluated by A260/A280 measurement. To detect the Wnt3a, GSK-3β, β-catenin, Runx 2, type I collagen, osteocalcin, BMP2, osterix, and GAPDH RNA transcripts, cDNA was analyzed using an ABI PRISM 7900 sequence detection system and TaqMan PCR Master Mix (Applied Biosystems, Foster City, CA). The cycle threshold (Ct) values were obtained, and the data were normalized to GAPDH expression using the ΔΔCt method to calculate the relative mRNA level of each target gene.
Small interfering RNA transfection On day 1, 2 × 10 5 BMSCs were plated onto a 6-well tissue culture plate in 2.5 mL of OPTI-MEM (Invitrogen, Carlsbad, CA) medium that was free of antibiotics and serum. The BMSCs were then transfected with human β-catenin small interfering (si)RNA or scrambled siRNA (Stealth RNAi, Invitrogen) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. After 8 h of transfection, the culture medium was changed to osteogenic medium with 10% FBS and the cells were exposed to HBO treatment. On days 4 and 7, the cells were re-transfected once and exposed to HBO. After an additional 24 h of culturing, the BMSCs were harvested for analysis. The silencing effect on β-catenin and downregulation of Runx 2 were detected by real-time PCR after the treatments.
Western blot analysis About 2.5 × 10 5 BMSCs were plated on 100 mm cell culture dishes. After culturing for 7 d or 14 d with or without HBO treatment, the cells were washed with PBS and extracted using M-PER protein extraction reagent (Thermo, USA). The protein content was quantitated using a protein assay kit (Pierce Biotechnology, IL), separated by 7.5% SDS-PAGE, and transferred onto membranes using a transfer unit (Bio-Rad, USA). After blocking, the membranes were incubated with 1000-fold diluted rabbit antibodies against Wnt3a, phosphor-LRP6, GSK-3β (Cell Signaling, MA, USA), LRP6 (Abcam, Cambridge, UK), or mouse antibodies against β-catenin (Millipore, Temecula, CA), β-actin (Millipore), Runx 2 (Millipore), Wnt1 (Abcam), Akt (Abcam), phosphor-Akt (Ser472) (Abcam), phosphor-GSK-3β (Ser9) (Abcam), phosphor-β-catenin (Ser33/37, Thr41) (Cell Signaling), BMP2 (Abcam), and osterix (Abcam). After washing, the membranes were further incubated for 2 h with 10,000-fold goat anti-mouse IgG (Calbiochem, USA) or goat anti-rabbit IgG (Millipore) conjugated to horseradish peroxidase. The membranes were then washed and rinsed with ECL detection reagents (Millipore). The bands were photographed using ECL Hyperfilm (Amersham Pharmacia Biotech, UK) and their intensity was quantified using an image-analysis system (Image-Pro plus 5.0).
Preparation of cytosolic and nuclear fractions for β-catenin detection About 2.5 × 10 5 BMSCs were plated on 100 mm cell culture dishes. After culturing for 7 d with or without HBO treatment, the cells were rinsed with PBS, treated with 0.05% trypsin, and then collected by centrifugation at 800 g. NE-PER nuclear and cytoplasmic extraction reagents (Thermo Science, USA) were used to isolate cytoplasmic and nuclear extracts from the cells. The protein content was quantitated using a protein assay kit (Pierce), and separated by 7.5% SDS-PAGE to detect β-catenin (Millipore) and TATA binding protein (TBP; Abcam).
On days 1, 4, and 7, the BMSCs were transfected with β-catenin siRNA or scrambled siRNA and exposed to HBO as described above. After an additional 24 h of culturing, the cytoplasmic and nuclear extracts were harvested for β-catenin detection as described above. (Invitrogen) were performed according to the manufacturer's instructions. Eight hours after transfection, the transfection medium was changed to osteogenic induction medium with 10% FBS, and the cells were exposed to HBO. On days 4 and 7, the cells were re-transfected once and exposed to HBO as described above. After an additional 24 h of culturing, the BMSCs were washed with PBS and harvested using 100 μL/well of passive lysis buffer (Promega). The cell lysates (20 μL) were evaluated for luciferase activity using a Dual-Luciferase Reporter Assay Kit (Promega). Luciferase activity was measured according to the manufacturer's instructions and normalized to the values for Renilla luciferase.
Construction of Runx2 promoter-luciferase constructs and expression vectors
Human Runx2 gene promoter fragments were generated by direct PCR amplification from human genomic DNA. The sequence-specific primer pairs were all designed to contain an XhoI site and a HindIII site for subsequent cloning. Desired DNA fragments were PCR amplified and inserted into the luciferase reporter vector pGL4.10 [luc2] (Promega). The inserts were positioned in the sense orientation relative to the luciferase coding sequence between the XhoI and HindIII sites. Proper insertion was verified by direct DNA sequencing. The 302-bp (−317 to −16) fragment containing the human Runx 2 promoter (Drissi et al., 2000; Zhang et al., 2009) was amplified from human DNA using the forward primer (5′-AGACTCGAGCCCTTAACTGCAGAGCTCTGCT-3′) and the reverse primer (5′-TGGCTG GTAGTGACCTGCGGAGATTA-3′). The fragment was inserted into pGL4.10 [luc2] via the XhoI and HindIII sites to obtain the vector pGL4-Runx 2-Luc.
Dual-luciferase reporter assay
Co-transfection of luciferase reporter plasmid DNA mixture (pGL4-Runx2-Luc: pGL4.74 [hRluc/TK] = 20:1) was performed using Lipofectamine LTX and PLUS reagent (Invitrogen). The cells were seeded in 6-well tissue culture plates at 2 × 10 5 cells/per well in 2.5 mL Opti-MEM (Invitrogen) at 12 h before transfection. On the day of transfection (day 1), the cells were exposed to DNA-Lipofectamine LTX and PLUS mixtures containing 2.5 μg of the luciferase reporter plasmid DNA mixture. At 8 h after transfection, the transfection medium was changed to osteogenic induction medium with 10% FBS and the cells were exposed to HBO. After 24 h, the cells were washed with PBS and harvested using 500 μL/well of passive lysis buffer (Promega). Cell lysates (20 μL) were evaluated for luciferase activity using a Dual-luciferase reporter assay kit (Promega). On days 4, 7, and 10, the cells were re-transfected once and exposed to HBO as described above.
Quantitative measurement of alkaline phosphatase activity After culturing for 7, 14, and 21 d with or without HBO treatment, the cultured cells were washed with PBS. A 5-mL aliquot of the alkaline phosphatase substrate buffer (50 mM glycine and 1 mM MgCl 2 , pH 10.5), containing soluble chromogenic alkaline phosphatase substrate (2.5 mM p-nitrophenyl phosphate), was added at room temperature. Twenty minutes after adding the substrate, 1 mL of the buffer was removed from the culture and mixed with 1 mL of 1 N NaOH to halt each reaction. The absorbance of each mixture was determined in triplicate using an ELISA plate-reader (MRX; Dynatech Labs) at 405 nm. Enzyme activity was expressed as n mole p-nitrophenol/min.
Calcium level quantification
After culturing for 7, 14, and 21 d with or without HBO treatment, the cultured cells were rinsed with PBS and placed into 5 mL of 0.5 N HCl. Calcium was extracted from the cells by shaking them for 24 h. Cellular debris was centrifuged and the calcium in the supernatant was measured using a Quantichrom calcium assay kit (DICA-500, Bioassay Systems, USA).
Alizarin Red staining
After culturing for 21 d with or without HBO treatment, the medium was aspirated from the dish. Cells were rinsed twice with 10 mL of PBS, and then fixed in 10% buffered formalin. After 45 min, the formalin was carefully aspirated and the cells were washed with distilled water. A 10-mL aliquot of freshly prepared 2% (w/v) Alizarin Red S solution (pH 4.2) was added, and the dishes were kept in the dark for 3 min, then thoroughly washed with distilled water. The presence of calcium deposit was indicated by the development of a bright orange-red precipitate on the mineralized matrix.
Wnt secretion factor assay ATP6V0 and ATP6V1 are 2 subunits of V-ATPase. After culturing for 1, 4, and 7 d with or without HBO treatment, the culture medium was collected and the cells were washed with PBS, after which the proteins were extracted using the M-PER protein extraction reagent (Thermo, USA). Each protein extraction was separated by 7.5% SDS-PAGE to detect ATP6V1 (Abcam) and β-actin (Millipore). The secreted Wnt3a in the collected medium was quantified by ELISA (USCN Life Science Inc., Wuhan, China).
RNAi treatment against V-ATPases
BMSCs were transfected with siRNA or scrambled siRNA against ATP6V1 (Santa Cruz) on days 1, 4, and 7 using the same protocol as previously described. Silencing was detected by Western blot analysis after the treatments. The secreted Wnt3a protein in the collected medium was quantified by ELISA (USCN).
Statistical analysis
Data are given as mean ± standard deviation of the results from 3 or 4 independent experiments. Data were analyzed using SPSS software. A p value less than 0.05 was defined as statistically significant.
In vivo study
All rabbits were cared for in accordance with the regulations of the National Institutes of Health of the Republic of China, under the supervision of a licensed veterinarian.
Surgical procedures Eight 14-week-old male New Zealand white rabbits were randomly divided into 2 groups. The first group (n = 4) went through intermittent 2.5 ATA HBO therapy, the second group (n = 4) was used as a control. Under sterile conditions and general anesthesia with ketamine hydrochloride (Ketalar, Parke-Davis, Taiwan) and Rompun (Bayer, Leverkusen, Germany) intravenous injection, a 5-cm incision was made over the medial aspect of the right tibia, and 4 stainless-steel screws were inserted. A uniplanar lengthening device (Traumafix, NY) was fixed with the 4 screws. The tibia was osteotomized at the tibiofibular junction between two inner screws using an airtome under saline irrigation. After a waiting period of 7 d, during which the interrupted blood circulation and endosteum in the marrow space were thought to recover, distraction was started at a rate of 0.5 mm every 12 h for 5 d (this produced a gap of 5 mm).
Animal exposure to intermittent HBO All of the animals were housed in a hyperbaric chamber (Perry Baromedical Corporation, Riviera Beach, FL). When they were in the chamber, the HBO group was exposed to 2.5 ATA of 100% O 2 for 25 min and then to normal air for 5 min at 2.5 ATA. The steps outlined above were repeated 3 times daily. The control group was exposed to 1 ATA of normal air. All the animals were allowed to freely move in their cages when they were not in the chamber.
Mechanical testing
All of the animals were sacrificed at 6 weeks after surgery and underwent mechanical testing. The tibiae bone segments containing the lengthening sites and their corresponding controls were aligned along their longitudinal axes and potted in holding tubes with methylmethacrylate. The potted samples were then mounted on a Material Testing System (MTS) machine (Bionix MTS, Minneapolis, MN). Specimens were tested until ultimate failure occurred during external rotation along their longitudinal axes at 1°/s. The percentage of maximal torque (maximal torque of lengthened bone / maximal torque of control bone) was calculated using the non-operated contralateral tibiae as an internal control. Differences between the 2 groups were analyzed by 2-tailed Student's t-test to determine the statistical significance. The fracture samples were microscopically and immunohistochemically examined to assess the failure site.
Tissue processing, hematoxylin-eosin (H&E) staining, and histologically quantifying After decalcification, the tissue blocks were cut in half through the defect area and embedded in paraffin. Five-micron sections were cut and stained with H&E. The changes of area in the fracture callus were quantified by using an image-analysis system (Image-Pro Plus 5.0). Immunohistochemical detection of Wnt3a, GSK-3β, β-catenin, Runx 2, and V-ATPase The tissue sections were deparaffinized, dehydrated, and treated with proteinase K (25 μg/mL, Sigma, MO) for 60 min. Endogenous peroxidase activity was blocked with 3% H 2 O 2 . The presence and distribution of Wnt3a, GSK-3β, β-catenin, Runx 2, and V-ATPase were determined using 5 μg/mL of anti-Wnt3a (Santa Cruz, CA), anti-Runx 2 (Santa Cruz), anti-β-catenin (BD Bioscience, CA), anti-V-ATPase (Santa Cruz), and anti-GSK-3β antibodies (Enzo Life Science, PA) at 4°C overnight. Subsequently, a biotinylated linking 2°Ab was used for 15 min. Bound immunoglobulin was detected using a LSAB peroxidase substrate kit (Dako, Carpinteria, CA) and 0.1% methyl green (Dako) was used for counterstaining.
Results
In vitro study
Flow cytometry analysis Primary adherent human BMSCs from 3 donors were cultured in control medium, and cells were analyzed for expression of BMSC markers using flow cytometry at passage 1. The percentage of cells expressing the BMSC markers CD146, CD105, Stro-1, α-SMA and CD34 were shown in Fig. 1 + cells in the cell preparations from 3 patients were calculated to be 27.6% ± 1.3%, 85.7% ± 5.8%, 32.7% ± 1.3%, 53.3% ± 2.1%, and 0.21% ± 0.09%, respectively.
Effect of HBO on cell proliferation rate of BMSCs A decrease in cell proliferation following HBO treatment was observed when the BMSCs were cultured in complete medium for 7, 10, and 14 d. No significant differences were detected in alkaline phosphatase activity between control and HBO group at each time point (Fig. 2A , *p N 0.05, **p b 0.05, ***p b 0.01, n = 3). However, an increase in cell proliferation following HBO treatment was noted when BMSCs were already committed to the osteoblast lineage which was confirmed by the evaluated expression of alkaline phosphatase activity after culturing for 7, 10, and 14 d in osteogenic conditions (Fig. 2B , *p N 0.05, **p b 0.05, ***p b 0.01, n = 3).
Effect of HBO on LRP6 phosphorylation and activation of the Wnt3a/β-catenin pathway The Western blot data showed that the protein levels of Wnt3a (1.54 ± 0.12-fold, *p b 0.05, n = 3), total LRP6 (2.03 ± 0.27-fold, *p b 0.05, n = 3), and phosphorylated LRP6 (2.59 ± 0.51-fold, **p b 0.01, n = 3) were upregulated after culturing for 7 d with HBO treatment. In addition, the activation of the Wnt3a pathway resulted in an enhanced expression of Wnt3a target gene, the protein cyclin D1 (1.90 ± 0.25-fold, *p b 0.05, n = 3) (Fig. 3A) .
The real-time Q-PCR data showed that the mRNA levels of Wnt3a (2.59 ± 0.57-fold, **p b 0.01 on D1; 2.21 ± 0.49-fold, **p b 0.01 on D4; 3.13 ± 0.75-fold, **p b 0.01 on D7, n = 3), β-catenin (1.41 ± 0.21-fold, p N 0.05 on D1; 1.68 ± 0.20-fold, *p b 0.05 on D4; 1.78 ± 0.12-fold, *p b 0.05 on D7, n = 3), and Runx2 (1.08 ± 0.11-fold, p N 0.05 on D1, 1.69 ± 0.18-fold, *p b 0.05 on D4, 1.72 ± 0.16-fold, *p b 0.05 on D7, n = 3) were upregulated, while that of GSK-3β (1.02 ± 0.03-fold, p N 0.05 on D1, 0.67 ± 0.11-fold, *p b 0.05 on D4, 0.54 ± 0.09-fold, *p b 0.05 on D7, n = 3) was downregulated after HBO treatment (Fig. 3B) . The silencing effect on β-catenin (Induction + HBO vs. Induction + HBO + siRNA, ***p b 0.01, Fig. 3C ) and downregulating effect for Runx2 (Induction + HBO vs. Induction + HBO + siRNA, **p b 0.05, Fig. 3D ) by β-catenin siRNA were detected by real-time PCR after the treatments. In Fig. 3 , the data shown are from cells culturing in osteogenic medium for 7 d. These cells are beginning to differentiate down to the osteoblastic pathway which was confirmed by the up-regulation of Runx 2 expressions.
The Western blot data showed that the protein levels of Wnt3a (1.54 ± 0.12-fold, p* b 0.05, n = 3), β-catenin (1.85 ± 0.13-fold, p** b 0.01, n = 3) and Runx2 (1.61 ± 0.11-fold, p** b 0.01, n = 3) were upregulated but that of GSK-3β (0.78 ± 0.05-fold, p* b 0.05, n = 3) was downregulated after HBO treatment (Fig. 4A) . HBO increased the osteogenic differentiation of the BMSCs as well as its effect on Wnt3a signaling. However, there was no significant effect of HBO on the Wnt 1 production.
The protein levels of β-catenin in the nuclear fractions were up-regulated after HBO treatment (2.44 ± 0.17-fold, p b 0.01, n = 3, Fig. 4B ). HBO increased the translocation of β-catenin from the cytosol into the nucleus. To confirm the effect of HBO on Runx2 expression via translocation of β-catenin, the increased protein levels of β-catenin and Runx2 by HBO treatment were all down-regulated through β-catenin siRNA treatment (β-catenin:0.32 ± 0.05-fold, p b0.01, n = 3; Runx2: 0.39 ± 0.15-fold, p b 0.05, n = 3; Fig. 4C ).
To further investigate the effects of HBO on the activation of Wnt3a and PI3K-Akt pathways, the levels of phospho-Akt (Ser 473), phospho-GSK-3β (Ser 9), and phospho-β catenin (Ser 33/37) have been examined and the results are shown in Fig. 5 . The relative optical density ratio (phospho-protein/protein) for Akt (41.7% ± 9% vs. 88.4% ±21.8%, *p b 0.05, n = 3) and GSK-3β (41.1% ± 5.1% vs. 64.84% ± 12%, *p b 0.05, n = 3) were both shown to be up-regulated while that of β-catenin (77.4% ± 9.5% vs. 29.8% ± 3.4%, **p b 0.01, n = 3) was down-regulated after HBO treatment.
Effect of HBO on the transcriptional activity of the β-catenin-TCF/LEF complex and Runx2 promoter/Luc gene activity In the nucleus, β-catenin interacts with TCF/LEF transcription factors and upregulates Wnt3a target genes. To further evaluate the activation of the β-catenin-TCF/LEF complex, we measured the activity of both TOP flash (containing the wild-type TCF binding sites) and FOP flash (mutant TOP flash) in BMSCs cultured in osteogenic medium after HBO treatment. Fig. 6A shows that there was increased TOP flash activity following HBO stimulation (1.58 ± 0.02-fold, **p b 0.01, n = 3), whereas the FOP flash activity (1.07 ± 0.05-fold, p N 0.05, n = 3) was not affected. These results demonstrate that HBO is able to enhance the transcription of genes that are targeted by the TCF transcription factor. To elucidate the mechanisms that underlie the effects of HBO on Runx2 gene expression in BMSCs Figure 3 Hyperbaric oxygenation promotes LRP6 phosphorylation to activate Wnt3a signaling and osteogeneic differentiation of BMSCs. (A) Western blot analysis revealed that the protein levels of Wnt3a (1.54 ± 0.12-fold, p b 0.05, n = 3), total LRP6 (2.03 ± 0.27-fold, p b 0.05, n = 3), and phosphorylated LRP6 (2.59 ± 0.51-fold, p b 0.01, n = 3) were upregulated after culturing for 7 d with HBO treatment. In addition, the activation of the Wnt3a pathway resulted in enhanced expression of cyclin D1 (1.90 ± 0.25-fold, p b 0.05, n = 3). (B) mRNA levels of Wnt3a (**p b 0.01 on D1, D4, and D7, n = 3), β-catenin (p N 0.05 on D1; *p b 0.05 on D4; *p b 0.05 on D7, n = 3), and Runx2 (p N 0.05 on D1; *p b 0.05 on D4; *p b 0.05 on D7, n = 3) were up-regulated, whereas that of GSK-3β (p N 0.05 on D1; *p b 0.05 on D4; *p b 0.05 on D7, n = 3) was downregulated after HBO treatment. (C) Silencing effect for β-catenin (Induction + HBO vs. Induction + HBO + siRNA, ***p b 0.01, n = 3) and (D) downregulating effect for Runx2 (Induction + HBO vs. Induction + HBO + siRNA, **p b 0.05, n = 3) by β-catenin siRNA were detected by real-time PCR after the treatments. Abbreviations: Ind, induction medium; I + H, induction medium + HBO, S-siRNA, scrambled siRNA. cultured in osteogenic medium, we examined its effect on the transcriptional regulation of cloned human Runx2/Luc reporter constructs. Our data showed that HBO upregulated Runx2/Luc gene transcription to 2.5-fold greater than that of the control using the Runx2 construct containing the −317 to −16 promoter regions (control vs. HBO: 4.09 ± 1.19-fold vs. 7.82 ± 2.13-fold, Effects of HBO on the activation of Wnt3a/β-catenin and PI3K-Akt pathways. The protein levels of Akt, GSK-3β, β catenin, phospho-Akt (Ser 473), phospho-GSK-3β (Ser 9), and phospho-β catenin (Ser 33/37) were examined. The relative optical density ratio (phospho-protein/protein) for Akt (41.7% ± 9% vs. 88.4% ± 21.8%, *p b 0.05, n = 3) and GSK-3β (41.1% ± 5.1% vs. 64.84% ± 12%, *p b 0.05, n = 3) was both up-regulated while that of β-catenin (77.4% ± 9.5% vs. 29.8% ± 3.4%, **p b 0.01, n = 3) was down-regulated after HBO treatment.
*p b 0.05 on D4, 5.24 ± 2.43-fold vs. 12.00 ± 0.69-fold, **p b 0.01 on D7, 6.73 ± 0.93-fold vs. 12.58 ± 1.37-fold, **p b 0.01 on D10, n = 4; Fig. 6B ).
Effect of long term exposure to HBO on mRNA and protein expression To deposit calcium, osteogenically induced BMSCs must enter the late stage of osteogenesis. We further investigated the long-term effects of HBO on BMSCs. The mRNA levels of type I collagen (2.99 ± 0.4-fold, *p b 0.05 on D14, n = 3) and osteocalcin (3.09 ± 0.28-fold, **p b 0.01 on D14, n = 3) were upregulated after HBO treatment (Fig. 7A) . In addition, HBO significantly increased the alkaline phosphatase activity (Fig. 7C) in the osteogenic induction medium. The deposition of a calcified matrix on the surface of the culture dish became evident by Alizarin Red staining. Greater positive staining of the matrix at the surface layer of the HBO group was observed compared to the control group (24.2% ± 2.7% vs. 63.9% ± 7.7%, **p b 0.01, n = 3, Fig. 7D ).
Effects of HBO on BMP-2 and osterix production HBO dose dependently increased the mRNA levels of BMP2 (1.31 ± 0.15 fold on D7, p N 0.05; 2.72 ± 0.52 fold on D14, *p b 0.05) and osterix (1.23 ± 0.12 fold on D7, p N 0.05; 4.52 ± 0.63 fold on D14, *p b 0.05). HBO also increased the protein levels of BMP2 (1.75 ± 0.25 fold, *p b 0.05) and osterix (2.57 ± 0.37 fold, *p b 0.05) on D14 (Fig. 8) .
Effect of HBO on ATP6V1 and Wnt3a secretion Protein levels of ATP6V1 were upregulated after HBO treatment in the cell lysates (Induction + HBO/Induction: 2.67 ±0.32-fold, *p b 0.05, n = 3) and the effect of HBO was reduced following ATP6V1 siRNA treatment (Induction +HBO + siRNA/Induction: 1.28 ± 0.13-fold, *p b 0.05, n = 3; Fig. 9A ). No significant effect on the ATP6V1 level was shown after scrambled siRNA treatment. The amount of Wnt3a in the collected culture medium was up-regulated after HBO treatment (Induction vs. Induction + HBO: 92.7 ± 6.3 vs. 143.7 ±16.5, *p b 0.05, n = 3) and the effect of HBO on Wnt3a secretion was reduced following ATP6V1 siRNA treatment (Induction + HBO vs. Induction + HBO + siRNA: 143.7 ± 16.5 vs. 87.1 ± 6.1, **p b 0.01, n = 3; Fig. 9B ). No significant effect on the Wnt3a levels was shown after scrambled siRNA treatment.
In vivo study
Surgery was successful in all 8 rabbits. Distraction was started at a rate of 0.5 mm every 12 h for 5 d and produced a gap of 5 mm. The manual evaluation before mechanical testing showed that at the sixth week, all the specimens from both groups were immobile.
Histology and mechanical testing
The distraction sites were filled with hard calluses in the tissue sections of the HBO group (Fig. 10B) . However, more fibrous tissue and cartilage were present in the control group (Fig. 10A) . The lengthened right tibiae exhibited spiral fractures across the regenerate site. The mechanical properties were shown in Table 1 . The mean percentage of maximal torque was 96.8% ± 5.6% in the HBO group (n = 4) and 73.7% ± 4.2% in the non-HBO group (n = 4). The data indicated that the mechanical properties of the HBO group were superior to those of the non-HBO group (*p b 0.01).
Immunohistochemistry
The callus is composed of calcified cartilage and newly formed woven bone. The callus area is larger in HBO group than in control group (1.71 ± 0.23 fold, *p b 0.01). Immunohistochemical analysis of the protein expression of Wnt3a (Figs. 10C,D) , GSK-3β (Figs. 10E,F) , β-catenin (Figs. 10G,H) , Runx2 (Figs. 10I,J) , and V-ATPase (Figs. 10K,L) was performed. The levels of Wnt3a (Fig. 10D) , β-catenin (Fig. 10H) , Runx2 (Fig. 10J) , and V-ATPase (Fig. 10L) were upregulated, while that of GSK-3β (Fig. 10F ) was downregulated after HBO treatment. The elevated V-ATPase levels (Fig. 10L) were associated with increased Wnt3a expression (Fig. 10D ) and the elevated β-catenin levels (Fig. 10H) were associated with increased Runx2 (Fig. 10J) in the HBO treated rabbits. The expression data related to Wnt3a/β-catenin signaling are consistent with our in vitro findings. The staining intensity and distribution of Runx2 expression were greater in the HBO treated rabbits compared with the controls, which reflects increased bone formation in the HBO group.
Discussion
Human BMSCs cultured in hypoxia show greater proliferation than those cultured in normoxic conditions (Grayson et al., 2006; Fehrer et al., 2007) . However, both inhibitory and enhancing effects of hypoxia on osteogenic differentiation have been reported (Grayson et al., 2006; Fehrer et al., 2007; Pattappa et al., 2011) . Because HBO increases the oxygen tension in vivo (Ueng et al., 1998; Korhonen et al., 1999) and in vitro (Ueng et al., 2013; Niu et al., 2013) , we used HBO to alter the hypoxic microenvironment for cell proliferation and differentiation and activate the oxygen sensitive pathways. Our findings support those of previous studies, which suggest that undifferentiated BMSCs and committed BMSCs could respond differently to oxygen signals (Fehrer et al., 2007) . HBO decreases cell proliferation when undifferentiated BMSCs are cultured in complete medium ( Fig. 2A) . However, increased levels of cell proliferation were induced by HBO treatment when the BMSCs were committed to the osteoblast lineage (Fig. 2B) . These findings were further validated by the evaluated expression levels of cyclin D1 after HBO treatment (Fig. 3A) . Although the responses of osteoblasts to HBO have been documented (Wu et al., 2007; Hsieh et al., 2010) , the direct effects of HBO on human BMSCs that are induced to differentiate down the osteoblastic pathway have, to the best of our knowledge, not been previously investigated.
Oxygen availability regulates stem cells via Wnt/β-catenin signaling (Mazumdar et al., 2010) . Because HBO has stimulatory effects on cell growth (Fig. 2B) , we wanted to identify the molecular mechanisms involved by assessing the Wnt/β-catenin pathway. Our data showed that the protein levels of Wnt3a, phosphorylated LRP6, and cyclin D1 were upregulated after culturing for 7 d with HBO treatment (Fig. 3A) . A key step after Wnt stimulation is the phosphorylation of the LRP6 intracellular domain. This phosphorylation event stabilizes the Wnt signaling transducer β-catenin (Bilic et al., 2007) . Activation of the Wnt3a pathway results in enhanced expression of the Wnt3a target gene, cyclin D1, which is required for G1/S phase traversal (Xiong et al., 1997) . Osteoblasts were induced to enter the S and G2/M phases of the cell cycle after HBO treatment (Hsieh et al., 2010) . HBO increases the proliferation of BMSCs that are beginning to differentiate down the osteoblastic pathway via Wnt3a signaling (Fig. 3) , which was in contrast to previous observations that hypoxia selectively activates Wnt/ β-catenin signaling in undifferentiated neural stem cells but not in differentiated neurons (Mazumdar et al., 2010) .
When BMSCs act as target cells, the canonical β-catenin signaling pathway can be stimulated in response to Wnt1, Wnt3a, and Wnt8 or by inhibition of GSK-3 (Westendorf et al., 2004) . Wnt/β-catenin directly stimulates Runx2 gene expression via the TCF-binding site (Gaur et al., 2005) . In the present study, the mRNA (Fig. 3B) and protein (Fig. 4A ) levels of Wnt3a, β-catenin, and Runx2 were upregulated, while that of GSK-3β was downregulated after HBO treatment. HBO increased β-catenin mRNA production to stimulate Runx2 mRNA expression and this was confirmed by β-catenin siRNA treatment (Figs. 3C-D) . In addition, accumulated β-catenin was subsequently translocated into the nucleus (Fig. 4B) where it upregulated Runx2 protein expression and this was also confirmed by β-catenin siRNA treatment (Fig. 4C) .
In the Wnt signaling pathway, β-catenin is phosphorylated by GSK-3β, which leads to its degradation via the ubiquitin/proteasome pathway (Zeng et al., 2005) . The activity of GSK-3β is reduced by phosphorylation of its N terminus at the Serine 9 residue by Akt (Cross et al., 1995) . Lithium, a pharmacological GSK-3 inhibitor, has been shown to enhance GSK-3 serine phosphorylation by activation of phosphatidylinositol 3-kinase (PI3-kinase)-dependent Akt (Chalecka-Franaszek and Chuang, 1999) . In the present study, HBO has similar effects which can increase the Serine 9 phosphorylation of GSK-3β through PI3-kinase-mediated phosphorylation of Akt (at the Serine 473 residue), thus decreases the activity of GSK-3β (Fig. 5) . Fig. 6A showed that there was increased TOP flash activity following HBO stimulation. The activation of the TOP flash reporter was specific to the Wnt3a genes (Gazit et al., 1999; Lu et al., 2004) . HBO increased Wnt3a expression, which enhanced the β-catenin-TCF transcriptional activity in this study.
The major isoforms of Runx2 involved in osteogenesis are type1 (T1) and type2 (T2) Runx2. T1 Runx2 is regulated by the proximal promoter P2; whereas T2 Runx2 is regulated by the distal promoter P1 (Sudhakar et al., 2001) . T2 Runx2 (P1 promoter) is induced upon stimulation with BMP2 or activation of the canonical Wnt and β-catenin/TCF1 pathways (Gaur et al., 2005) . Hypoxia or TWIST did not inhibit P1 but it did inhibit P2 promoter activity in BMSCs undergoing osteogenic differentiation (Yang et al., 2011) . In the present study, HBO activated the canonical Wnt and β-catenin/TCF1 pathways to increase Runx2/Leu promoter activity (Fig. 6B) . However, the effects of HBO on the individual P1 and P2 promoter activities need to be further investigated. Wnt signaling activates the endogenous BMP2 gene through a TCF response enhancer region (Zhang et al., 2013) . BMP-2 stimulates the expression of osterix which is required for osteoblast differentiation and bone formation (Nakashima et al., 2002; Lee et al., 2003) . Because HBO activated the Wnt/β-catenin/TCF pathways (Fig. 6B) , we further investigated the effects of HBO on BMP-2 production and found that HBO dose dependently increased the mRNA expression of BMP2 and osterix. In addition, HBO also increased the protein levels of BMP2 and osterix (Fig. 8) . Wnt/β-catenin signaling is an upstream activator of BMP2 expression in osteoblasts (Zhang et al., 2013) . Our results provided novel insights into the nature of functional cross talk integrating the BMP and Wnt/β-catenin pathways in osteoblastic differentiation after HBO treatment.
Osteoblasts originate from BMSCs via a stepwise maturation process. During the early stages of osteogenesis, the cell cannot deposit calcium to form mineralized bone (Ducy et al., 1997) . To deposit calcium, the cells must enter the late stage Figure 10 Beneficial effects of HBO on bone formation via regulation of Wnt3a/β-catenin signaling. The distraction sites were filled with calcified cartilage and newly formed woven bone in the tissue sections of the HBO group (B, 40 ×). However, more fibrous tissue and cartilage were present in the control group (A, 40 ×). The levels of Wnt3a (D, 100 ×), β-catenin (H, 100 ×), Runx2 (J, 100 ×), and V-ATPase (L, 100 ×) were upregulated, whereas that of GSK-3β (F, 100 ×) was downregulated after HBO treatment. The staining intensity and distribution of the Runx2 expression levels were greater in the HBO treated rabbits compared with the controls, which reflects greater bone formation in the HBO group. Control group: A, C, E, G, I, and K. HBO group: B, D, F, H, J, and L. of osteogenesis (Nakashima et al., 2002) . We further investigated the long-term effects of HBO (14 and 21 d) on the osteogenic differentiation of BMSCs and found that HBO significantly increased the expression of osteogenic markers, including type I collagen, osteocalcin (Fig. 7A) , alkaline phosphatase activity (Fig. 7B) , and calcium (Fig. 7C) . Enhanced positive Alizarin Red staining through the matrix at the surface layer of the HBO group was also seen compared to the control group (Fig. 7D) .
V-ATPases is a pH regulator in acidic subcellular compartments including the Golgi complex, vesicles, and lysosomes. Wnt3a secretion requires its binding to the carrier protein wntless (WLS) and Wls-dependent secretion of Wnt3a was shown to require vacuolar acidification (Coombs et al, 2010) . In the presence of acidification inhibitors, the Wnt3a-Wls complex is able to reach the cell surface but the release of Wnt3a from Wls is hindered (Coombs et al, 2010) . Treatment of cells with siRNA targeting 2 subunits of V-ATPase (ATP6V1 and ATP6V0) inhibited Wnt signaling (Cruciat et al., 2010) . When osteogenically differentiated BMSCs act as Wnt producing cells, increased V-ATPase expression (Fig. 9A ) and Wnt3a secretion (Fig. 9B) were induced by HBO treatment. Secretion of Wnt3a is impaired upon inhibition of V-ATPase. Wnt3a is retained in the producing cells, and is therefore, unable to move into the culture medium during ATP6V1 siRNA treatment (Fig. 9B) .
Bone repair requires the mobilization of adult skeletal stem cells to allow deposition of cartilage and bone at the injury site. These stem cells are believed to come from multiple sources including the bone marrow and periosteum (Colnot, 2009) . HBO treatment increases the number of circulating hematopoietic stem cells (Thom et al., 2006) and endothelial precursor cells (Liu and Velazquez, 2008) . However, there is no convincing evidence that BMSCs can be liberated from the bone marrow. HBO effects on circulating BMSCs have not been elucidated. Previously, we showed that HBO increased bone mineral density and torsional strength of lengthened tibia in a rabbit model (Ueng et al., 1998) . In the present study, we further demonstrated that Wnt3a/β-catenin signaling plays a crucial role in bone healing after HBO treatment. The levels of Wnt3a (Fig. 10D) , β-catenin (Fig. 10H) , Runx2 (Fig. 10J) , and V-ATPase (Fig. 10L) were upregulated, whereas that of GSK-3β (Fig. 10F ) was downregulated after HBO treatment. Therefore, HBO increased β-catenin production or decreased β-catenin degradation by upregulating Wnt3a or down-regulating GSK-3β expression. Expression of stabilized β-catenin in cells committed to the osteoblast lineage improves osteogenesis, thereby leading to enhanced bone healing.
Both canonical Wnt pathway (Wnt3a/β-catenin) and noncanonical Wnt pathway (Wnt5a, which signals mainly through the Wnt/calcium) have been shown to regulate the differentiation state of BMSCs. In addition, several microRNAs (miRNAs) have recently been discovered as important regulators of osteoblast gene expression, such as Mir-31 (Baglìo et al., 2013) , Mir-93 (Yang et al., 2012) , Mir-141, Mir-200a, Mir-133a, Mir-204, and Mir-211 (Chen et al., 2013) . It is currently not clear which pathway is at work regulating the differentiation state of the cells.
Osteoblast maturation requires the phenotype promoting activity of the transcription factor Runx2, which controls both cell growth and differentiation. Runx2 is hyper-phosphorylated by CDK1/cyclin B during mitosis and dynamically converted into a hypo-phosphorylated form by PP1/PP2A-dependent dephosphorylation after mitosis to support the post-mitotic regulation of Runx2 target genes (Rajgopal et al., 2007) . In the present study, the activation of the Wnt3a pathway by HBO treatment resulted in an enhanced expression of Wnt3a target gene, the protein cyclin D1 ( Fig. 2A) , which is required for cell cycle G1/S transition (Sherr and Roberts, 1999) . Further studies are required to investigate the expression of CDK1/cyclin B and PP1/PP2A in osteoblasts after HBO treatment.
Several studies have concluded that HBO has different effects on osteoblast proliferation in vitro. Wong et al. showed that 100% O 2 at 2 ATA once daily inhibited growth of primary osteoblasts and resulted in a significant increase in apoptosis (Wong et al., 2008) . Comparatively, Hsieh et al. found that providing 50% O 2 at 2.5 ATA twice daily increased growth of an osteoblast cell line (Hsieh et al., 2010) . In the present study, 100% O 2 at 2.5 ATA once every 36 h promoted proliferation of committed BMSCs (Fig. 2B) . The differences among the present results and those reported by Wong et al. and Hsieh et al. may stem from the use of different cells (committed BMSCs, primary culture osteoblasts, and an osteoblast cell line), different levels of pressure (1 ATA, 2 ATA, and 2.5 ATA), different O 2 concentrations (21%, 50%, and 100%), and different treatment durations (once daily, twice daily, and once every 36 h). Because 100% O 2 at 2 ATA once daily inhibited growth of primary osteoblasts (Wong et al., 2008) , the duration was modified from once daily to once every 36 h and found to have a positive effect on cell proliferation in this study (Fig. 2B) . HBO treatment not only increased cell proliferation of committed BMSCs, but also suppressed the apoptosis in degenerated intervertebral disc cells and osteoarthritic chondrocytes (Ueng et al., 1998) in previous studies. Our data support the notion that different cell types have distinct growth responses after exposure to HBO in vitro.
Environmental oxygen levels affect tissue vascularization and fracture healing. A previous study suggested that hyperoxia (50% O 2 and 1 ATA) increased tissue vascularization but did not significantly alter osteogenesis during the early stages of fracture healing (Lu et al., 2013) . Most of the inspired atmospheric oxygen was carried by hemoglobin (Hb) and delivery to the fracture site. After Hb saturation, the oxygen level may not be high enough to increase the osteogenesis in the avascular fracture site. In this study, HBO (hyperbaric oxygen, a combination of 100% O 2 and 2.5 ATA) increased osteogenesis of bone healing. After Hb saturation, HBO may result in greater amounts of O 2 dissolved in plasma to improve the environmental oxygen levels at the avascular fracture site than hyperoxia treatment only. The additive effects of increased pressure and increased O 2 were demonstrated in this study. Long-term and repeated HBO treatments may increase oxidative stress (Korhonen et al., 1999) ; however, tolerance to HBO treatment can be extended by intermittent exposure. The authors used a clinical HBO protocol in this study. Because exposure to HBO in clinical protocols is rather brief (typically b 2 h/d), studies show that antioxidant defenses are adequate so that biochemical stresses related to increases in ROS are reversible (Korhonen et al., 1999) .
Conclusions
Considering the previous studies and our findings, we propose the following model: When osteogenically differentiated BMSCs act as Wnt3a-producing cells, the level of Wnt3a is upregulated after HBO treatment. In addition, protein levels of ATP6V1 and Wnt3a secretion were also upregulated after HBO treatment. When osteogenically differentiated BMSCs act as Wnt3a targeting cells, phosphorylated LRP6, β-catenin, TCF-dependent transcription, Runx2 promoter/Luc gene activity, and the expression of osteogenic markers were upregulated after HBO treatment. Because Wnt/β-catenin signaling is an upstream activator of BMP2 expression in osteoblasts, we further found that HBO dose dependently increased the BMP2 and osterix production. Finally, we showed that the beneficial effects of HBO on bone formation were related to Wnt3a/ β-catenin signaling in a rabbit model. After understanding the regulatory factors and molecular mechanisms, HBO may serve as a therapeutic approach to increase bone healing in clinical studies. 
